Photo from wikipedia
Radioiodine (RAI) is the mainstay of treatment for differentiated thyroid carcinoma (DTC) following total thyroidectomy. Nevertheless, about 5% of patients with DTC are RAI-refractory (RAI-R). Understanding the molecular mechanisms associated… Click to show full abstract
Radioiodine (RAI) is the mainstay of treatment for differentiated thyroid carcinoma (DTC) following total thyroidectomy. Nevertheless, about 5% of patients with DTC are RAI-refractory (RAI-R). Understanding the molecular mechanisms associated with DTC during progression towards RAI-R DTC, including thyroid-stimulating hormone levels, may help to explain the pathophysiology of challenging RAI-R DTC clinical cases. Graphical Abstract
Keywords:
refractory;
molecular evidence;
thyroid carcinoma;
differentiated thyroid;
radioiodine
Journal Title: Cancer Cell International
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer Cell International
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!